Innovate Biopharmaceuticals Announces Participation at the Jefferies 2018 London Healthcare Conference
October 31 2018 - 9:00AM
Innovate Biopharmaceuticals, Inc. (“Innovate”) (Nasdaq: INNT), a
clinical stage biotechnology company focused on developing novel
therapeutics for autoimmune and inflammatory diseases, today
announced it intends to present at the Jefferies 2018 London
Healthcare Conference. The conference is being held on
November 14-15, 2018. The presentation will be at 10:40am (GMT) on
November 14, 2018.
To see the full list of upcoming events where the Company
intends to present or participate, please visit Innovate’s web site
under Events & Presentations.
About Innovate Biopharmaceuticals, Inc. (Nasdaq:
INNT): Innovate is a clinical stage biotechnology company
focused on developing novel therapeutics for autoimmune and
inflammatory diseases. Innovate’s lead drug candidate, larazotide
acetate, has a mechanism of action that renormalizes the
dysfunctional intestinal barrier by decreasing intestinal
permeability and reducing antigen trafficking, such as gliadin
fragments in celiac disease, and bacterial toxins and immunogenic
antigens in NASH. In several diseases, including celiac
disease, NASH, Crohn’s disease, ulcerative colitis, and
irritable bowel syndrome (IBS) the intestinal barrier is
dysfunctional with increased permeability.
In celiac disease, larazotide is the only drug which has
successfully met its primary endpoint with statistical significance
in a Phase 2b efficacy clinical trial (342 patients). Innovate
completed the End of Phase 2 Meeting with the FDA in 2017
and is preparing to begin Phase 3 registration clinical trials for
celiac disease, targeted to commence in the first half of 2019.
Nearly 600 subjects have been exposed to larazotide in clinical
trials, and a safety profile comparable to placebo has been
demonstrated. Larazotide has received Fast Track designation from
the FDA for celiac disease.
Forward Looking Statements This press release
includes forward-looking statements including, but not limited to,
statements related to our operations and business strategy. The
forward-looking statements contained in this press release are
based on management’s current expectations and are subject to
substantial risks, uncertainty and changes in circumstances. Actual
results may differ materially from those expressed by these
expectations due to risks and uncertainties, including, among
others, those related to our ability to obtain additional capital
on favorable terms to us, or at all, the success, timing and cost
of our drug development program and our ongoing or future clinical
trials, the lengthy and unpredictable nature of the drug approval
process, and our ability to commercialize our product candidates if
approved. These risks and uncertainties include, but may not be
limited to, those described in our Quarterly Report on Form 10-Q
filed with the SEC on August 14, 2018, and in any subsequent
filings with the SEC. Forward-looking statements speak only as of
the date of this press release, and we undertake no obligation to
review or update any forward-looking statement except as may be
required by applicable law.
Innovate Biopharmaceuticals, Inc. Jennifer K.
Zimmons, Ph.D. Investor Relations Tel: +1 917.214.3514 Email:
jzimmons@innovatebiopharma.com www.innovatebiopharma.com
Innovate Biopharmaceutic... (NASDAQ:INNT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Innovate Biopharmaceutic... (NASDAQ:INNT)
Historical Stock Chart
From Apr 2023 to Apr 2024